Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication

Back to Jobs

SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the signing of a co-promotion agreement with Mission Pharmacal Company (“Mission”), a well-established

Apply Now